Product Name:
ANXA1-pY207
Product Number:
ab-pn503
Target Full Name: Annexin A1
Target Alias: Annexin A1; Annexin I; annexin I (lipocortin I); Annexin-1; ANX1; anxa 1; ANXA1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; LPC1; p35; Phospholipase A2 inhibitory protein
Product Type Specific: ANXA1 phosphosite-specific antibody
Antibody Code: PN503
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y207
Protein UniProt: P04083
Protein SigNET: ANXA1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ANXA1 sequence peptide Cat. No.: PE-04AEY95
Antibody Immunogen Sequence: RAL(pY)EAG(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R204 to G210; in the beginning of the third Annexin domain. The effect of Y207 phosphorylation is unclear. This is the major in vivo phosphorylation site in ANXA1 with 559 mass spectrometry reports recorded in PhosphoSitePlus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity of a target-sized protein by Western blotting in HeLa cells, andMedium detection in A431 and MCF7 cells. Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog | Zebra fish.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 36-38 kDa.
Antibody Specificity: High-very high
Antibody Cross Reactivity: Five other cross-reactive proteins in HeLa + phenylarsine oxide (PAO)+vanadate; 37 kDa target, 5 other cross-reactive proteins in A431 + EGF; 37 kDa target, 5 other cross-reactive proteins in MCF7 + Insulin.
Related Product 1: ANXA1 (203-210) pY207 antibody blocking peptide (Cat. No.: PE-04ARB95)
Related Product 2: ANXA2 Y238 phosphorylation antibody (Cat. No.: AB-PN504)
Related Product 3: ANXA11 Y482 phosphorylation antibody (Cat. No.: AB-PN871)
Scientific Background: Annexin A1 (ANXA1) plays important roles in the innate immune response as effector of glucocorticoid-mediated responses such as down-regulation of the early phase of the inflammatory response and as a regulator of the inflammatory process by promoting resolution of inflammation and wound healing. It functions at least in part by activating the formyl peptide receptors to regulate cell proliferation, apoptosis, differentiation, and migration. It inhibits leukocyte extravasation (migration), neutrophil infiltration, and the activity of phospholipase, thereby reducing inflammatory mediators like eicosanoids. It promotes angiogenesis and wound closure by activating MAPK and NFkB pathways. Its expression is altered in various cancers (e.g., down-regulated in triple-negative breast cancer, up-regulated in hairy cell leukemia). This description may include information annotated by UniProt and/or Google AI.